Ibrutinib is a medication that blocks the activity of a protein called Bruton's tyrosine kinase (BTK) and is primarily used as a first-line agent for treating chronic lymphocytic leukemia (CLL). Here, BTK is linked to B-cell chronic lymphocytic leukemia.